- Omeros Corporation (NASDAQ:OMER) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).
- The response comprises a comprehensive briefing package drafted in close collaboration with external clinical, regulatory, and legal experts addressing the points raised by the FDA.
- Omeros concurrently requested a Type A meeting with FDA to resolve any outstanding items.
- Related Link: Omeros Stock Falls As FDA Asks For More Clinical Narsoplimab Data In HSCT-TMA.
- Narsoplimab is the first drug candidate submitted to FDA for approval in HSCT-TMA.
- It has Breakthrough Therapy and Orphan designations in both HSCT-TMA and IgA nephropathy.
- Related: Omeros' Narsoplimab Shows Improved, Stabilized Renal Function At Three Years.
- Price Action: OMER shares are up 1.94% at $5.26 during after-hours trading on Wednesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Omeros Submits Response To FDA Regarding Narsoplimab Application In HSCT-TMA
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks